Dr. Yedidya Saiman Offers Insight to the Philadelphia Inquirer on New FDA-Approved Medication for Fatty Liver Disease

Yedidya Saiman, MD, PhD, Assistant Professor of Medicine at the Lewis Katz School of Medicine at Temple University, offered insight to the Philadelphia Inquirer on Rezdiffra, or resmetirom, which has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of scarring and inflammation caused by abnormal accumulations of fat in the liver. The condition is known as metabolic dysfunction-associated steatohepatitis (MASH), or fatty liver disease. Dr. Saiman was not involved in the study of Rezdiffra.